IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
-- Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's -- ...
Stay updated with breaking news from Ram Mukunda. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's -- ...
IGC Pharma, Inc. today announces the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence and one of the world's top researchers. Dr. Arbelaez will support the development of...
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation - Interim Data: Study Achieves Primary End Point Demonstrating...
IGC Pharma, Inc. today announced that it has appointed Terry Lierman as an independent director to its board of directors. Mr. Lierman is currently Co-Chair of the Board of Advisors at the...
IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") today announced that it has appointed Terry Lierman as an independent director to its board of directors. Mr. Lierman is currently Co-Chair of the Board of Advisors at the Institute of Human...